Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma

Table 2 Comparison of background factors between groups A and B (Mann-Whitney U test/χ² test)

	Group A	Group B	P value
Number	27	9
Age, yr (range)	67 (43-77)	58 (37-77)	0.168
Gender, male/female	22/5	8/1	0.848
Etiology, HBV/HCV/non-BC	6/17/4	3/6/0	0.432
Child-Pugh score, A/B/C	5/16/1	3/3/2	0.136
Platelet count (× 104)	12. 4 (3.0-22.7)	11.1 (3.8-17.2)	0.880
Albumin (g/dL)	3.1 (2.1-4.1)	3.0 (2.2-4.0)	0.755
ALP, max (U/L)	824 (365-4447)	798 (422-1350)	0.476
PT (%)	79 (45-117)	74 (47-99)	0.199
Tumor size 2 cm over, Y/N	19/8	5/4	0.888
Tumor location, unilobular/bilobular	12/15	4/5	0.652
Hepatocellular carcinoma.	15/12	5/4	0.647
T1-T3/T4
Grade of portal vein invasion, VP0-3/VP4	24/3	5/4	0.039
VP, present/absent	17/10	6/3	0.721
Grade of bile duct invasion, Bismuth classification 1-3/4	16/11	6/3	0.782
Previous treatment, Y/N	18/9	9/0	0.046
HAI, Y/N	9/18	4/5	0.842
TACE, Y/N	8/19	4/5	0.888
Interventional radiology, Y/N	14/13	5/4	0.716
Hepatectomy, Y/N	1/26	4/5	0.009
The number of stent, single/multiple	13/14	8/1	0.036

HCV: Hepatitis C virus; HBV: Hepatitis B virus; ALP: Alkaline phosphatase; HAI: Hepatic arterial infusion chemotherapy; TACE: Transcatheter arterial chemoembolization; Y: Yes, N: No.